Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Decreases By 37.3%

Neuronetics, Inc. (NASDAQ:STIM) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 607,300 shares, a decline of 37.3% from the November 15th total of 969,100 shares. Based on an average trading volume of 452,500 shares, the days-to-cover ratio is presently 1.3 days.

Neuronetics Price Performance

NASDAQ:STIM opened at $1.12 on Friday. The company has a market cap of $33.99 million, a P/E ratio of -0.91 and a beta of 2.25. The firm’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.28. Neuronetics has a one year low of $0.52 and a one year high of $5.07. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87.

Institutional Trading of Neuronetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP lifted its position in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the last quarter. First Eagle Investment Management LLC increased its stake in shares of Neuronetics by 33.4% during the second quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock worth $1,870,000 after purchasing an additional 260,000 shares during the period. Acadian Asset Management LLC lifted its holdings in Neuronetics by 23.7% during the 2nd quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock worth $587,000 after purchasing an additional 62,628 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Neuronetics by 63.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock valued at $244,000 after purchasing an additional 52,450 shares during the period. Finally, Dorsey & Whitney Trust CO LLC grew its holdings in Neuronetics by 97.1% in the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock valued at $173,000 after buying an additional 47,228 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.